Spyre Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Spyre Therapeutics

04/03/2024 13:02

* Spyre Therapeutics Inc  SYRE.OQ  reported a quarterly
adjusted
loss of $4.05​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of $-4.50.  The mean expectation of seven analysts
for the quarter was for a loss of 78 cents per share. Wall
Street expected results to range from $-1.15 to -28 cents per
share.
    * Reported revenue was zero​; analysts expected $220.00
thousand. 
    * Spyre Therapeutics Inc's reported EPS for the quarter was
a loss
of $4.05​.
    * The company reported a quarterly loss of $63.18 million.
    * Spyre Therapeutics Inc shares had risen by 38.9% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 18.7%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 7 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Spyre
Therapeutics Inc is $35.50 

This summary was machine generated from LSEG data March 4 at
01:01 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.78          -4.05          Missed
 Sep. 30 2023      -0.84          -9.34          Missed
 Jun. 30 2023      -4.50          -41.50         Missed
 Mar. 31 2023      -4.50          -5.00          Missed